Heidelberg Spectralis OCT

描述（由申请人提供）：我们申请的目的是获得一台海德堡光谱OCT仪器，用于哥伦比亚大学哈克尼斯眼科研究所的研究。这里的许多教职员工正在进行视网膜退行性疾病的研究，他们依靠最新的成像能力，图像分析和临床分期来与基因分析相关联。在这个应用程序上指定的用户都领导了使许多患有眼病的人受益的项目，如年龄相关性黄斑变性（AMD）、Stargardt病、视网膜色素变性和青光眼。他们的工作将有助于我们了解这些疾病，并改善患有这些疾病的患者可用的治疗选择。Spectralis OCT提供更快、更高分辨率、多模态视网膜层可视化的能力可以帮助所有这些项目，同时为眼科研究所的患者护理管理提供日常改进。Spectralis系统的另一个优点是，它有一个专用的第二眼动追踪设备，确保眼球运动补偿，从而获得的图像与光谱域光学相干断层扫描（SD-OCT）扫描完全匹配。例如，自体荧光异常的位置可以与SD-OCT上看到的结构变化精确相关。这种能力对于视网膜疾病的多模式研究至关重要。这也使得后续检查能够在完全相同的位置进行扫描，以可靠地测量疾病进展。这对于目前使用的单独成像模式是不可能的。改进后的技术将被史密斯博士与生物医学工程系联合使用，以改进他们现有的图像分析软件，该软件可以量化彩色眼底、红外和自身荧光图像中的萎缩和地理萎缩。Allikmets博士正在研究AMD的遗传学，他可以使用该仪器将他的遗传学发现与该疾病的临床阶段联系起来。Sparrow博士对Stargardt病的研究、Tsang博士对色素性视网膜炎的研究以及Hood博士对青光眼的研究也将采用类似的方法。眼科研究所已经有能力维护和运行仪器，工作人员完全有能力使用Spectralis，并承诺在哥伦比亚大学进行的所有研究项目中公平分配其使用。

DESCRIPTION (provided by applicant): The goal of our application is to obtain a Heidelberg Spectralis OCT instrument for research at Columbia University's Harkness Eye Institute. The many faculty members here who are conducting research on retinal degenerative disorders rely on the latest imaging capabilities, image analysis and clinical staging to correlate with genetic analyses. The users specified on this application have all headed projects that have benefited many individuals suffering from eye diseases such as age-related macular degeneration (AMD), Stargardt disease, retinitis pigmentosa and glaucoma. Their work will aid in our understanding of these diseases and improve the treatment options that are available to patients living with these conditions. The ability of the Spectralis OCT to provide faster, higher resolution, multimodal visualization of the retinal layers can assist all of these projects while providing daily improvement in the management of patient care at the Eye Institute. Another advantage of the Spectralis system is that there is a dedicated, second eye tracking device which ensures compensation for eye movement and thus that the acquired images are exactly in register with the spectral domain optical coherence tomography (SD-OCT) scans. For example, the location of autofluorescence abnormalities can be precisely correlated with structural changes seen on SD-OCT. This capability is critical for multimodal study of retinal disease. This also enables follow-up examinations to be scanned in exactly the same location for reliable measurement of disease progression. This is not possible with the separate imaging modalities currently in use. The improved technology will be used by Dr. Smith in conjunction with the Department of Biomedical Engineering to improve their existing image analysis software, which quantifies drusen and geographic atrophy in color fundus, infrared, and autofluorescence images. Dr. Allikmets, who is examining the genetics of AMD, can use the instrument to correlate his genetic findings with the clinical stage of the disease. Similar uses will be made in Dr. Sparrow's research on Stargardt disease, Dr. Tsang's research on retinitis pigmentosa and Dr. Hood's work on glaucoma. The Eye Institute already has the capability of maintaining and running the instrument, with staff that are fully capable of using the Spectralis, and a commitment to allocate its usage fairly among all the research projects being conducted at Columbia. Public Health Relevance: Since age-related macular degeneration (AMD) is the leading cause of blindness in the United States, improvement in treatment options and preventive care resulting from improved understanding of the disease would have a large impact on public health. Research done at the Columbia University Harkness Eye Institute on AMD, as well as other eye diseases, would greatly benefit from the technology of the Spectralis, a new imaging instrument with faster image acquisition and improved retinal visualization.